NovoCure Ltd - Company Profile
Powered by 
All the sales intelligence you need on NovoCure Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how NovoCure Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with NovoCure Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
NovoCure Ltd (NovoCure) is an oncology company with a focus on the development and commercialization of novel delivery systems for the treatment of brain, thoracic and abdomen cancers. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. The company markets TTF-based delivery systems, Optune Lua for the treatment of malignant pleural mesothelioma; and Optune Gio for the treatment of glioblastoma. The products are indicated in combination with standard chemotherapies. The company has operations in five regions, namely, United States, Germany, Japan, Greater China and Other international markets. NovoCure is headquartered in Zug, Switzerland.
Headquarters
Switzerland
Address
Neuhofstrasse 21, Baar, Zug, 6340
Website
www.novocure.com
Telephone
44 1534 756700
No of Employees
1,488
Industry
Medical Equipment
Ticker Symbol & Exchange
NVCR (NASD)
Revenue (2024)
$605.2M
18.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
18.6%
(2024 vs 2023)
Market Cap*
$2.1B
Net Profit Margin (2024)
XYZ
31.5%
(2024 vs 2023)
* As of and is in US$
NovoCure Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Optune Lua: Malignant Pleural Mesothelioma | Optune Lua |
| Optune Gio: Glioblastoma | Optune |
| Pipeline Programs: | Novocure |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In March, the company received approval from Japan’s Ministry of Health, Labour and Welfare for insurance reimbursement for Optune Lua to treat non-small cell lung cancer. |
| 2026 | Regulatory Approval | In February, the company secured approval from the U.S. Food and Drug Administration for Optune Pax for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel. |
| 2025 | Regulatory Approval | In September, the company received approval from Japan’s Ministry of Health, Labour and Welfare for Optune Lua for use with PD-1/PD-L1 inhibitors to treat adult patients with unresectable advanced/recurrent non-small cell lung cancer. |
Competitor Comparison
| Key Parameters | NovoCure Ltd | MDxHealth SA | MagForce AG | Advanz Pharma Corp Ltd | Monteris Medical Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Belgium | Germany | United Kingdom | United States of America |
| City | Zug | Herstal | Berlin | London | Minnetonka |
| State/Province | - | - | Baden-Wurttemberg | England | Minnesota |
| No. of Employees | 1,488 | 312 | 69 | 680 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William F. Doyle | Chairman | Executive Board | 2016 | 62 |
| Francis Leonard | Chief Executive Officer | Senior Management | 2025 | 45 |
| Christoph Brackmann | Chief Financial Officer | Senior Management | 2025 | 51 |
| Mukund Paravasthu | Chief Operating Officer | Senior Management | 2024 | 55 |
| Nicolas Leupin, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2024 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer